https://www.live-feeds.com/feed/this-biotech-s-lsd-based-drug-just-treated-depression-now-the-stock-is-sky-highContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/this-biotech-s-lsd-based-drug-just-treated-depression-now-the-stock-is-sky-highhttps://www.live-feeds.com/feed/this-biotech-s-lsd-based-drug-just-treated-depression-now-the-stock-is-sky-high#u12584Thu, 25 Jun 2026 08:42:00 +0000Definium Therapeutics reported strong results from its Phase 3 Emerge study for DT120 ODT, an LSD-based depression pill. A single dose significantly reduced major depressive disorder symptoms in a 149-patient trial. The company's stock rose sharply following the announcement on June 22, 2026.What's confirmed:Definium Therapeutics' LSD-based drug DT120 ODT met its primary and key secondary endpoints in the Phase 3 Emerge trial.The Emerge trial included 149 patients with major depressive disorder.The primary endpoint was met with a statistical significance of pDefinium Therapeutics sha